Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

FDA issue Eczema drug warning

The American Food and Drugs Administration (FDA) has approved an updated label containing a boxed warning about cancer risks for pimecrolimus (Elidel)® and tacrolimus (Protopic)®.

The FDA is taking this action to "ensure that healthcare providers and patients are aware of the possible long-term risks of these products". This follows rare reports of cancer in patients using these products, although at this time no causal relationship has been established.

Action: The safety of these products is still under review and as detailed here, clinicians should ensure these products are used as per the NICE Technology Appraisal and within the product licence. (Note: neither product is licensed for used in patients under 2 years old).

Summary of Product Characteristics for Tacrolimus
Summary of Product Characteristics for Pimecrolimus

Share 'FDA issue Eczema drug warning' on Email Share 'FDA issue Eczema drug warning' on Delicious Share 'FDA issue Eczema drug warning' on Digg Share 'FDA issue Eczema drug warning' on Facebook Share 'FDA issue Eczema drug warning' on Google+ Share 'FDA issue Eczema drug warning' on reddit Share 'FDA issue Eczema drug warning' on StumbleUpon Share 'FDA issue Eczema drug warning' on Twitter

atomic-wealth

No Comments to “FDA issue Eczema drug warning”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,320 spam comments.

atomic-wealth
fond-illness
summer